• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
  • Issues
    • Current Issue
    • Issue Archives
  • Editor's Update
  • Advertise
  • Reprints
  • Authors
    • Author Instructions
    • Submission Portal
  • Reviewers
  • Contact

Search

Interview with David Hahn, MD, Interventional Radiologist

  • Tue, 7/6/10 - 11:07am
  • 0 Comments
  • 2733 reads
Start Page: 
166
End Page: 
167


An Interventional Radiology Laboratory’s Experience with the REEF HP PTA Balloon Catheter



Tell us about your experience with the REEF HP PTA balloon catheter.

I have had the opportunity to use the REEF HP PTA balloon catheter (Invatec, Inc., Bethlehem, Pennsylvania) since its U.S. release back in January 2010. I have been using the balloon in a busy interventional radiology lab providing the full spectrum of vascular and non-vascular interventional services in a tertiary care health system. Essentially, we needed a product that could serve as a “workhorse” angioplasty balloon for a variety of cases.

How many cases have you performed using the REEF HP PTA balloon catheter?

Overall, I have used the REEF balloon in approximately 50 cases.

In what types of lesions is the REEF HP PTA balloon catheter used?
I have used the REEF HP PTA balloon catheter in a variety of cases including dialysis access management, declotting of arteriovenous grafts and fistulas, as well as during interventions in arterial peripheral vascular disease patients.

Describe the design features of the REEF balloon catheter and how it is deployed.

The REEF HP balloon catheter has many of the design features that are necessary in a high-pressure balloon used for a variety of applications. First and foremost, the REEF has a rated burst pressure up to 22 atmospheres, which is extremely useful when faced with the particularly fibrotic and resistant lesions seen in dialysis outflow cases. The neointimal hyperplasia that constitutes the cellular biology of these lesions translates to a stenosis that is often difficult to efface at standard inflation pressures. In addition, these patients frequently have multiple angioplasties performed at the same site over the years due to restenosis and repetitive buildup of neointima. In the past, these lesions were typically dilated using a standard-pressure balloon, reserving the more costly high-pressure balloons in the event of primary balloon failure. A competitively priced workhorse high-pressure balloon such as the REEF could alleviate the cost of opening two balloons for the same lesion and decrease the overall procedure time. By “workhorse”, I am referring to the type of balloon that is most frequently stocked in the endovascular suite and is the most commonly used balloon in the laboratory. When such a balloon can address a stenosis requiring both standard and high pressures without compromising the working sheath diameter, it becomes an added design feature in a balloon.

This leads us to the second useful feature, which is its low-profile diameter. The catheter can be used through the standard 6- to 8-French sheaths required for most dialysis access intervention. In addition, it has very good trackability over a guidewire, which becomes useful when navigating acute angles such as the retrograde access required for addressing a stenosis at the arterial anastomosis of an arteriovenous graft or fistula. With other high-pressure balloons on the market, I have frequently found kinking of the catheter to be an issue, especially when dealing with this type of lesion. In comparison, the REEF balloon has tended to be both kink-resistant and trackable. Lastly, the balloon appears to have a very good compliance profile. This is particularly important when treating a lesion that requires high pressure in order to efface the waist of the balloon. A compliant or semi-compliant balloon may assume an hourglass shape near burst pressures, and actually overdilate near the ends of the balloon. This can be potentially harmful to the non-diseased portion of the vessel, particularly in arteries where the risk of dissection is higher. The REEF balloon maintains its shape with minimal overdilation at the ends.

What is the learning curve with this device?

Like any new device, no matter how straightforward, there is a small learning curve. Using an angioplasty balloon is a subjective experience, and different operators become comfortable with different balloons depending on personal techniques and the type of practice one has. For a high-pressure balloon, the operator must feel confident that the balloon will consistently perform without rupture at its rated burst pressure. In the event of balloon rupture, one must be able to successfully retrieve the torn balloon without worrying about distal embolization of a balloon fragment. Almost every operator who has used a balloon in this setting has experienced balloon rupture. With the current inventory of balloons on the market, rupture is usually not a large concern. When testing a new balloon, the operator has to feel that the new product will perform in a fashion consistent with or better than its competitors in terms of rupture, inflation/deflation times, trackability and compliance. From my experience, the REEF balloon requires a learning curve similar to that of the other balloons available.

Can you describe a case that illustrates the unique design features of the REEF balloon catheter?

  • 1
  • 2
  • next ›
  • last »
image description image description

Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.

  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Alex Dulnikowski, Classified Sales Manager
    (800) 237-7285, ext. 205

vdm Blogs

A New Algorithm to Treat Patients with Peripheral Vascular Disease

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT

In-Stent Restenosis in the SFA Remains a Significant Unresolved Problem

Frank J Criado MD FACS FSVM

Support Comes From Many Directions

Richard R. Heuser MD FACC FACP FESC FSCAI

Pedal Artery Access: Advances in Management of Critical limb ischemia

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT

The SFA School of Thought Continues

Lawrence A. Garcia MD
more »

Vascular Newswire

  • Vascular Solutions Launches Reprocessing Service For Closurefast Vein Catheters
    Fri, 02/03/12 - 1:14pm
  • AMA: Halt Implementation of ICD-10
    Thu, 02/02/12 - 11:56am
  • NHS Makes GBP200 Non-Drug Hypertension Treatment Device Available on Prescription
    Wed, 02/01/12 - 11:06am
  • AngioDynamics to Acquire Navilyst Medical
    Tue, 01/31/12 - 2:48pm
more »

Clinical Events Calendar

  • American Venous Forum 24th Annual Meeting
    Wed, 02/08/2012 - Sat, 02/11/2012
    Orlando, FL, United States
  • JIM 2012
    Thu, 02/09/2012 - Sat, 02/11/2012
    Rome, Italy
  • Cardiovascular Care Update 2012 (CVC)
    Fri, 02/10/2012 - Sat, 02/11/2012
    Scottsdale, AZ, United States
more »

Poll

Do you think that endostaples will soon become important tools in the hands of aortic interventionists?:
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2012 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2012 HMP Communications